Understand how intelligent study design, focused data collection, and faster analytics can help clinical teams deliver meaningful results that sustain investor momentum.

Eli Lilly’s oral GLP-1 therapy, orforglipron, met all primary and key secondary endpoints in the Phase III ACHIEVE-2 and ACHIEVE-5 studies, showing significant A1C reduction, weight loss, and ...

Preserving trial integrity. Clinical trials are susceptible to timing. Delays in investigational product delivery can stall ...

Gain insight into why early toxicology readiness and strong scientific collaboration with CRO partners are critical to ...

Designing adhesion and durability for biopharmaceuticals in the most extreme cold chain environments.

Uncover how improving data accuracy and leveraging synthetic control arms can optimize trial efficiency, reduce costs, and ...

Sustainability should be central to clinical trial design and considerate of how digital tools such as electronic clinical ...

By 2025, approximately three-quarters of pharma companies (78%) reportedly had DEI initiatives integrated into their ...

More signals don't always mean better detection. To maximize impact, KRI frameworks should follow a few guiding principles, including: Prioritize critical KRIs (linked to study objectives, safety, and ...

Examine strategies for validating, monitoring, and safely deploying configurable AI agents to ensure compliance and ...

Applied Clinical Trials recently conducted its State of the Industry survey, capturing perspectives on the current clinical ...

In nearly all cases, the Phase III protocol had a higher number of endpoints, procedures, and eligibility criteria relative ...